daw
08-27-2003, 07:58 PM
Barrett's Esophagus and Esophageal Adenocarcinoma
Posted 08/22/2003
from Medscape Primary Care
Question
What is the incidence and lifetime prevalence of adenocarcinoma of the esophagus among cohorts of patients with Barrett's?
Response
from M. Brian Fennerty, MD, 08/22/2003
This question cannot be accurately answered because there are no good cohort studies of Barrett's esophagus patients without dysplasia. Indeed, some experts have suggested that estimates in the literature have grossly overestimated the true incidence because of publication bias. What is known is that all Barrett's esophagus patients have a 30- to 100-fold increased risk of cancer, but given that the absolute incidence of this cancer is low, the overall rate in Barrett's esophagus patients remains low despite this magnitude of increased risk. Most have suggested that the data indicate that an individual with Barrett's esophagus without dysplasia has a lifetime risk of less than 5%. The annual incidence of dysplasia among Barrett's esophagus patients without dysplasia appears to be less than 1% in a recent consortium database of over 1000 such patients.
Suggested Readings
Shaheen N, Ransohoff DF. Gastroesophageal reflux, Barrett's esophagus and esophageal cancer. JAMA. 2002;287:1972-1981.
Sharma P, Reker D, Falk G, et al. Progression of Barrett's esophagus to high-grade dysplasia and cancer: Preliminary results of the BEST trial. Gastroenterology. 2001;120:A16.
About the Panel Members
M. Brian Fennerty, MD, Professor of Medicine, Section Chief of Gastroenterology, Oregon Health Sciences University, Portland, Oregon
Posted 08/22/2003
from Medscape Primary Care
Question
What is the incidence and lifetime prevalence of adenocarcinoma of the esophagus among cohorts of patients with Barrett's?
Response
from M. Brian Fennerty, MD, 08/22/2003
This question cannot be accurately answered because there are no good cohort studies of Barrett's esophagus patients without dysplasia. Indeed, some experts have suggested that estimates in the literature have grossly overestimated the true incidence because of publication bias. What is known is that all Barrett's esophagus patients have a 30- to 100-fold increased risk of cancer, but given that the absolute incidence of this cancer is low, the overall rate in Barrett's esophagus patients remains low despite this magnitude of increased risk. Most have suggested that the data indicate that an individual with Barrett's esophagus without dysplasia has a lifetime risk of less than 5%. The annual incidence of dysplasia among Barrett's esophagus patients without dysplasia appears to be less than 1% in a recent consortium database of over 1000 such patients.
Suggested Readings
Shaheen N, Ransohoff DF. Gastroesophageal reflux, Barrett's esophagus and esophageal cancer. JAMA. 2002;287:1972-1981.
Sharma P, Reker D, Falk G, et al. Progression of Barrett's esophagus to high-grade dysplasia and cancer: Preliminary results of the BEST trial. Gastroenterology. 2001;120:A16.
About the Panel Members
M. Brian Fennerty, MD, Professor of Medicine, Section Chief of Gastroenterology, Oregon Health Sciences University, Portland, Oregon